TEKTURNA HCT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tekturna Hct, and what generic alternatives are available?
Tekturna Hct is a drug marketed by Noden Pharma and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty-two patent family members in twenty-five countries.
The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this compound. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.
DrugPatentWatch® Generic Entry Outlook for Tekturna Hct
Tekturna Hct was eligible for patent challenges on March 5, 2011.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 13, 2028. This may change due to patent challenges or generic licensing.
There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for TEKTURNA HCT
International Patents: | 32 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 18 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TEKTURNA HCT |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TEKTURNA HCT |
What excipients (inactive ingredients) are in TEKTURNA HCT? | TEKTURNA HCT excipients list |
DailyMed Link: | TEKTURNA HCT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TEKTURNA HCT
Generic Entry Date for TEKTURNA HCT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TEKTURNA HCT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Wayne State University | Phase 4 |
University of Alabama at Birmingham | Phase 4 |
Mayo Clinic | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for TEKTURNA HCT
Paragraph IV (Patent) Challenges for TEKTURNA HCT
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TEKTURNA HCT | Tablets | aliskiren hemifumarate; hydrochlorothiazide | 150 mg/12.5 mg 150 mg/25 mg 300 mg/12.5 mg 300 mg/25 mg | 022107 | 1 | 2014-03-07 |
US Patents and Regulatory Information for TEKTURNA HCT
TEKTURNA HCT is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TEKTURNA HCT is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TEKTURNA HCT
Galenical formulations of organic compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Noden Pharma | TEKTURNA HCT | aliskiren hemifumarate; hydrochlorothiazide | TABLET;ORAL | 022107-001 | Jan 18, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Noden Pharma | TEKTURNA HCT | aliskiren hemifumarate; hydrochlorothiazide | TABLET;ORAL | 022107-004 | Jan 18, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Noden Pharma | TEKTURNA HCT | aliskiren hemifumarate; hydrochlorothiazide | TABLET;ORAL | 022107-002 | Jan 18, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Noden Pharma | TEKTURNA HCT | aliskiren hemifumarate; hydrochlorothiazide | TABLET;ORAL | 022107-003 | Jan 18, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TEKTURNA HCT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Noden Pharma | TEKTURNA HCT | aliskiren hemifumarate; hydrochlorothiazide | TABLET;ORAL | 022107-002 | Jan 18, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Noden Pharma | TEKTURNA HCT | aliskiren hemifumarate; hydrochlorothiazide | TABLET;ORAL | 022107-001 | Jan 18, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Noden Pharma | TEKTURNA HCT | aliskiren hemifumarate; hydrochlorothiazide | TABLET;ORAL | 022107-003 | Jan 18, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Noden Pharma | TEKTURNA HCT | aliskiren hemifumarate; hydrochlorothiazide | TABLET;ORAL | 022107-004 | Jan 18, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Noden Pharma | TEKTURNA HCT | aliskiren hemifumarate; hydrochlorothiazide | TABLET;ORAL | 022107-004 | Jan 18, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TEKTURNA HCT
When does loss-of-exclusivity occur for TEKTURNA HCT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1565
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 07263261
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0713338
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 54872
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 07001837
Estimated Expiration: ⤷ Sign Up
China
Patent: 1472566
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 088986
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 34968
Estimated Expiration: ⤷ Sign Up
Patent: 11439
Estimated Expiration: ⤷ Sign Up
Patent: 91878
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 0800297
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 5425
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 62556
Estimated Expiration: ⤷ Sign Up
Patent: 09541239
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 6779
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 08016533
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 527
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 2937
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 090262
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 080373
Estimated Expiration: ⤷ Sign Up
Patent: 120990
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 91058
Estimated Expiration: ⤷ Sign Up
Patent: 09101971
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0809773
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1442272
Estimated Expiration: ⤷ Sign Up
Patent: 090021353
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 04979
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 57137
Estimated Expiration: ⤷ Sign Up
Patent: 0808358
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 08528
Estimated Expiration: ⤷ Sign Up
United Kingdom
Patent: 12540
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TEKTURNA HCT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Luxembourg | 91563 | ⤷ Sign Up | |
Hungary | 230882 | Renin inhibitort tartalmazó kombinációs készítmények (Combinations containing a renin inhibitor) | ⤷ Sign Up |
Australia | 2368002 | ⤷ Sign Up | |
European Patent Office | 0678503 | Amides des acides delta-amino-gamma-hydroxy-oméga-aryl alkanoiques possédant une activité d'inhibiteurs d'enzyme notamment une activité d'inhibiteurs de rénin (Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities) | ⤷ Sign Up |
Norway | 2009011 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TEKTURNA HCT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0678503 | CA 2011 00027 | Denmark | ⤷ Sign Up | |
1507558 | 122012000031 | Germany | ⤷ Sign Up | PRODUCT NAME: ALISKIREN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON (KOMPONENTE 1), AMLODIPIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON (KOMPONENTE 2) UND HYDROCHLORTHIAZID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON (KOMPONENTE 3); NAT. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: SCHWEIZ 61678 01 - 05 20110705 |
1915993 | C300625 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414 |
2305232 | C201930070 | Spain | ⤷ Sign Up | PRODUCT NAME: ALISKIREN HEMIFUMARATO + HIDROCLOROTIAZIDA; NATIONAL AUTHORISATION NUMBER: EU/1/08/491/001-080; DATE OF AUTHORISATION: 20090116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/08/491/001-080; DATE OF FIRST AUTHORISATION IN EEA: 20090116 |
1602370 | SZ 11/2009 | Austria | ⤷ Sign Up | PRODUCT NAME: KOMBINATION ENTHALTEND ALISKIREN ALS FREIE BASE ODER ALS PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, UND HYDROCHLORTHIAZID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |